Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

N/ACompletedNCT03509896

Bristol-Myers Squibb463 enrolled

Overview

Observational medical record review of newly diagnosed CML-CP participants in China

Study Type

OBSERVATIONAL

Enrollment

463

Conditions

Chronic Myeloid Leukemia Philadelphia Chromosome Chronic Myeloid Leukemia in Chronic Phase

Interventions

Non-InterventionalOTHER

Non-Interventional

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Ph+ CML-CP patients who were diagnosed between August 1, 2014 to August 1, 2016 * 18 years or older at time of diagnosis Exclusion Criteria: * Participants once enrolled in any interventional clinical trial for CML * Participants whose records are not available Other protocol defined inclusion/exclusion criteria could apply

Locations (1)

Local Institution

Tianjin, Tianjin Municipality, China

Outcomes

Primary Outcomes

Number of participants receiving each first-line treatment option

Time frame: 2 years

Number of participants with complete cytogenetic response

Complete Cytogenetic Response (CCyR): 0% Ph+ cells in metaphase in bone marrow (BM)

Time frame: 2 years

Number of participants with major molecular response (MMR)

Major molecular response (MMR) is defined as 3-log reduction in International Scale of BCR-ABL mRNA

Time frame: 2 years

Number of participants of each initial dose schema

Time frame: 2 years

Starting dose of each first-line agent

Time frame: 2 years

Secondary Outcomes

Distribution of demographic characteristics

Including age, sex, height, weight

Time frame: 2 years

Distribution of clinical characteristics

Including health insurance and comorbid conditions

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.